• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

ACCC Launches ICLIO for Community Oncologists


ICLIO promises to guide oncologists in community care practices to navigate the growing field of immuno-oncology.

Immuno-oncology, which has transformed the cancer treatment landscape, is rapidly being adopted into clinical practice and yielding promising results in oncology. However, questions about indications, biomarkers, cost of care, adverse effects, and reimbursement, remain. To help guide oncologists in community care practices to navigate this growing field, The Association of Community Cancer Centers has launched the Institute for Clinical Immuno-Oncology (ICLIO). Lee S. Schwartzberg, MD, FACP, chair of ICLIO had introduced ICLIO to our managed care readers through an article in Evidence-Based Oncology back in February.

ICLIO is open to all ACCC members, which includes more than 2000 cancer programs and 20,000 providers nationwide. ACCC estimates that nearly 60% of all cancer patients in the United States are treated by someone in the ACCC network.

Read the press release: http://prn.to/1dKhTgN

Related Videos
Dr Guru Sonpavde
Video 2 - "Adverse Events & Existing Treatment Options for Dry Eye Disease"
Overview of Dry Eye Disease (DED) Causes and Treatments
Video 12 - "Harnessing Indication-Specific Data on Biosimilars"
Video 11 - "An Overview of Biosimilar Extrapolation During FDA Approval"
Video 3 - "Overview of BCG-Unresponsive Bladder Cancer Treatments Landscape"
Video 2 - "Bladder Cancer with FGFR Alterations: THOR-2 Cohort 1 Study at ESMO 2023"
Related Content
© 2023 MJH Life Sciences
All rights reserved.